116 filings
ARS
2023 FY
NKTX
Nkarta Inc
25 Apr 24
Annual report to shareholders
4:35pm
DEFA14A
NKTX
Nkarta Inc
25 Apr 24
Additional proxy soliciting materials
4:34pm
DEF 14A
NKTX
Nkarta Inc
Definitive proxy
25 Apr 24
4:31pm
PRE 14A
NKTX
Nkarta Inc
Preliminary proxy
15 Apr 24
5:12pm
8-K
NKTX
Nkarta Inc
28 Mar 24
Other Events
4:08pm
424B5
7qjghd
25 Mar 24
Prospectus supplement for primary offering
8:15pm
8-K
ujvfp53g1l jy38l6m2
25 Mar 24
Regulation FD Disclosure
6:05am
8-K
268g vjlweu6kvu4kd
21 Mar 24
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:15pm
8-K
dtewvt2o nviiuud
8 Jan 24
Regulation FD Disclosure
8:50am
S-8
3bd2gdmxjc 07t
3 Jan 24
Registration of securities for employees
4:15pm
8-K
3efu94tcb85e z15fu
9 Nov 23
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:06pm
8-K
x38st1i6hfnibd
17 Oct 23
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
7:06am
8-K
s2b2imrtzb7vnlc
16 Oct 23
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
4:07pm
8-K
bkwufx3tsia
10 Aug 23
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
7:05am
8-K
4mk5lw fp
5 Jul 23
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
4:09pm
8-K
fqu zxsfx
27 Jun 23
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
7:07am
8-K
ootw 0pr0zi
26 Jun 23
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
4:07pm